Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Anthera Pharmaceuticals Incex32_1.htm
EX-31.2 - EXHIBIT 31.2 - Anthera Pharmaceuticals Incex31_2.htm
EX-31.1 - EXHIBIT 31.1 - Anthera Pharmaceuticals Incex31_1.htm
EX-23.1 - EXHIBIT 23.1 - Anthera Pharmaceuticals Incex23_1.htm
EX-10.41 - EXHIBIT 10.41 - Anthera Pharmaceuticals Incex10_41.htm
EX-10.39 - EXHIBIT 10.39 - Anthera Pharmaceuticals Incex10_39.htm
EX-10.38 - EXHIBIT 10.38 - Anthera Pharmaceuticals Incex10_38.htm
EX-10.37 - EXHIBIT 10.37 - Anthera Pharmaceuticals Incex10_37.htm
EX-10.36 - EXHIBIT 10.36 - Anthera Pharmaceuticals Incex10_36.htm
EX-10.35 - EXHIBIT 10.35 - Anthera Pharmaceuticals Incex10_35.htm
10-K - Anthera Pharmaceuticals Inca22118010k.htm
Exhibit 32.2


Certification Pursuant to

Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350



I, May Liu, certify, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Anthera Pharmaceuticals, Inc. on FORM 10-K for the fiscal year ended December 31, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Anthera Pharmaceuticals, Inc.



March 5, 2018
By:
/s/ May Liu
 
   
May Liu
   
Senior Vice President, Finance & Administration
   
(Principal Financial Officer)